News | Myriad Genetics

New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey

Dec 15, 2021 | Products

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

Dec 14, 2021 | Corporate

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

Nov 23, 2021 | Products

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

Nov 22, 2021 | Pipeline | Products

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

Nov 02, 2021 | Financial

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

Oct 27, 2021 | Financial

Myriad Genetics Names Pamela Wong as Chief Legal Officer

Oct 18, 2021 | Corporate

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Oct 11, 2021 | Products

Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp

Sep 13, 2021 | Corporate

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

Sep 08, 2021 | Products

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

Aug 03, 2021 | Financial

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Aug 02, 2021 | Pipeline | Products

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

Jul 28, 2021 | Financial

New research reveals most Americans can’t identify the symptoms of depression

Jul 28, 2021 | Products

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

Jul 21, 2021 | Corporate | Products

Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions

Jul 01, 2021 | Corporate

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

Jun 16, 2021 | Corporate

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Jun 04, 2021 | Corporate

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Jun 01, 2021 | Corporate | Products

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

May 24, 2021 | Corporate | Financial

Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business

May 20, 2021 | Corporate

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

May 19, 2021 | Pipeline | Products

Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference

May 05, 2021 | Corporate

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

May 03, 2021 | Financial

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

May 03, 2021 | Corporate

Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

May 03, 2021 | Corporate

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

Apr 28, 2021 | Products

Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

Apr 27, 2021 | Corporate

Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Apr 27, 2021 | Corporate

Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

Mar 29, 2021 | Corporate

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan

Mar 24, 2021 | Products | Pipeline

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

Mar 02, 2021 | Pipeline | Products

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

Feb 23, 2021 | Financial

Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives

Feb 18, 2021 | Corporate

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

Feb 16, 2021 | Financial

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

Feb 12, 2021 | Pipeline | Products

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

Feb 11, 2021 | Corporate

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Feb 08, 2021 | Products

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

Feb 02, 2021 | Products

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Jan 19, 2021 | Products

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Jan 11, 2021 | Products

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

Jan 08, 2021 | Products | Pipeline

Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations

Jan 05, 2021 | Corporate

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference

Jan 04, 2021 | Corporate

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

New Year’s Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

Myriad Genetics Names Pamela Wong as Chief Legal Officer

Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Myriad Genetics Completes Sale of Myriad Autoimmune’s Vectra Testing Business to LabCorp

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021

New research reveals most Americans can’t identify the symptoms of depression

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

Myriad Genetics Completes Sale of Myriad RBM to IQVIA’s Q2 Solutions

Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference